CureDuchenne launches CureDuchenne Link, a centralized data hub that directly connects data and biosamples provided by the Duchenne and Becker muscular dystrophy community with scientists and drug developers around the globe.
By reducing the search for data connected to biosamples and removing barriers that typically cost researchers and drug developers time and money, CureDuchenne Link looks to accelerate exploration into new gene therapies, exon-skipping and other targeted Duchenne therapeutic development. Now clinicians, researchers and drug developers worldwide have access to a single, unified, HIPAA-compliant platform for a holistic view of biosamples integrated with clinical, genomic and patient reported data, CureDuchenne explains in a media release.
“With the launch of CureDuchenne Link, we hope to break down existing information silos and offer qualified researchers access to participant data and biosamples in one all-encompassing platform.
“Duchenne and Becker are complex diseases with thousands of mutations. To effect real change, we need research into every one of those mutations. We turn to the entire community for help and encourage them to participate in a monumental shift for research and treatment development. Together, we WILL cure Duchenne.”
— Debra Miller, founder and CEO of CureDuchenne
Participation is voluntary, free and widely accessible for all participants. CureDuchenne Link partnerships allow biosamples to be collected conveniently and efficiently, no matter where participants receive their care.
CureDuchenne Link harnesses the strengths of global leaders from technology and healthcare, including BC Platforms, DevIQ, GeneDx, Infinity Biologix, Precision for Medicine and TRiNDS, per the release.
“We are confident CureDuchenne Link will drive muscular dystrophy research forward, and are excited to support CureDuchenne by bringing our expertise to this monumental project.”
— Lauren Morgenroth, CEO of Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS)
Nation-wide enrollment opens on July 9, 2021.
Register Now for CureDuchenne FUTURES National Conference
CureDuchenne Invests in Entrada Therapeutics to Accelerate Drug Development
CureDuchenne Launches Online Resources to Build and Engage the Duchenne Community